Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic 'Rewards' Added To, 'Evergreening' Requirements Dropped From North American Trade Deal

Executive Summary

USMCA is looking more and more like a win for generic firms, who hope it will be template for future trade agreements.

You may also be interested in...



UK-US Free Trade Deal Plans Disappoint Industry

The UK has published its negotiating mandate for talks on a free trade deal with the US. As expected, intellectual property protection figures prominently, but the life sciences industry sees little merit in the government’s approach. It also warns that the UK’s future relationship with the EU could lead to greater regulatory burdens and costs.

Industry ‘Disappointed’ By UK Plans For Free Trade Deal With US

The UK has published its negotiating mandate for talks on a free trade deal with the US. As expected, intellectual property protection figures prominently, but the life sciences industry sees little merit in the government’s approach. It also warns that the UK’s future relationship with the EU could lead to greater regulatory burdens and costs.

Generic Association CEO Davis Jumps To Wholesalers Group

Association for Accessible Medicines’ interim leader is General Counsel Jeffrey Francer; Chip Davis’ four-and-half year tenure included a total rebrand of the association, a significant legislative victory with the CREATES act – and an abrupt departure for the Healthcare Distribution Alliance.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel